AUM Biosciences partners with National Cancer Centre Singapore (NCCS) to develop new cancer drugs
With an aim to develop new cancer drugs for Asian cancer patients, AUM Biosciences is proud to announce our collaboration with the National Cancer Centre Singapore (NCCS) on a joint research that will use precision and digital medicine techniques. Our combined efforts will shorten the time that it would normally take to test and develop new drugs.
The collaboration will combine NCCS’ highly-regarded Patient Derived Xenograft (PDX) laboratory model capabilities and knowledge on drug discovery, with AUM Biosciences’ expertise in clinical drug development.
With NCCS’ niche in Asian-specific diseases and AUM’s focus on Asia-centric cancer treatments, this collaboration between our two Singapore parties will deliver huge benefits for patients here in Singapore and in the region.